Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2019 / N 1

Группы пациентов с атеросклерозом, требующие особого внимания и использования интенсивной липидснижающей терапии с помощью ингибиторов PCSK9
Ю.А. Карпов

Список литературы

1. Russian Federal State Statistics Service (Rosstat). Health care in Russia 2017. Statistical handbook. Moscow: 2017. 170 p. (In Russian).
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Atherosclerosis 2016 Oct;253:281-344.
3. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. European Heart Journal 2018 Sep;39(33):3021-104.
4. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. The American Journal of Cardiology 1995 Sep;76(9):69C-77C.
5. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
6. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
guideline on the management of blood cholesterol: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Journal of the American College of Cardiology 2019 Jun;73(24):3168-209.
7. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov;344(8934):1383-9.
8. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 2010 Apr;35(2):139-51.
9. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). The American Journal of Cardiology 2003 Jul;92(2):152-60.
10. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology 2014 Aug;64(5):485-94.
11. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation: Cardiovascular Genetics 2012 Apr;5(2):257-64.
12. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. Journal of the American College of Cardiology 2005 Oct;46(8):1405-10.
13. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2018 Jan;39(2):119-77.
14. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima–media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007 Mar;297(12):1344-53.
15. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Reichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. The New England Journal of Medicine 2011 Dec;365(22):2078-87.
16. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007 Feb;297(5):499-508.
17. Nicholls SJ, Ballantyne C, Barter P, Chapman M, Erbel R, Libby P, Raichlen J, Uno K, Puri R, Kataoka Y, Wolski K, Nissen S. Regression of coronary atheroma volume in patients receiving high dose statin therapy: analysis of the SATURN study. Journal of the American College of Cardiology 2012 Mar;59(13):E1502.
18. Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circulation Journal 2010 May;74(5):818-26.
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine 2008 Nov;359(21):2195-207.
20. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010 Nov;376(9753):1670-81.
21. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015 Apr;385(9976):1397-405.
22. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 Aug;380(9871):581-90.
23. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. The Cochrane Database of Systematic Reviews 2013 Jan;(1):CD004816.
24. Ezhov MV, Sergiyenko IV, Aronov DM, Arabidze GG, Akhmedzhanov NM, Bazhan SS, Balakhonova TV, Barbarash OL, Boytsov SA, Bubnova MG, Voyevoda MI, Galyavich AS, Gornyakova NB, Gurevich SV, Drapkina OM, Duplyakov DV, Yeregin SYa, Zubareva MYu, Karpov RS, Karpov YuA, Koziolova NA, Konovalov GA, Konstantinov VO, Kosmacheva ED, Martynov AI, Nebiyeridze DV, Pokrovskiy SN, Ragino YuI, Skibitskiy VV, Smolenskaya OG, Chazova IE, Shalnova SA, Shaposhnik II, Kukharchuk VV. Diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Russian recommendations, 6th rev. The Journal of Atherosclerosis and Dyslipidemias 2017;3(28):5-22 (In Russian).
25. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. The New England Journal of Medicine 2018 Nov;379(22):2097-107.
26. Herttua K, Martikainen P, Batty GD, Kivimäki M. Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke. Journal of the American College of Cardiology 2016 Apr;76(13):1507-15.
27. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017 Jun;389(10088):2473-81.
28. Khan S, Holbrook A, Shah BR. Does Googling lead to statin intolerance? International Journal of Cardiology 2018 Jul;25:25-7.
29. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal 2018 Jul;39(27):2526-39.
30. Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD Cohort. PLoS One 2016 Mar;11(3):e0151587.
31. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation 2009. Available from: https://www.fda.gov/media/116737/download Accessed 2019 Jun 23.
32. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. Journal of Hepatology 2012 Feb;56(2):374-80.
33. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal 2015 May;36(17):1012-22.
34. Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, Lanfear D, Virani S, Morris PB; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Hypertension; Council on Quality of Care and Outcomes Research; Council on Functional Genomics and Translational Biology. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2016 Nov;134(21):e468-95.
35. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology 1999;39:1-17.
36. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis. Supplements. 2002 May;3(1):35-40.
37. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, Sivaramalingam B, Iserman E, Mustafa RA, Jedraszewski D, Cotoi C, Haynes RB. Interventions for enhancing medication adherence. The Cochrane Database of Systematic Reviews 2014 Nov;(11):CD000011.
38. Shalnova SA, Deyev AD, Metelskaya VA, Evstifeyeva SE, Rotar OP, Zhernakova YuV, Boytsov SA, Balanova YuA, Gomyranova NV, Imayeva AE, Kapustina AV, Kontsevaya AV, Litynskaya OA, Mamedov MN, Muromtseva GA, Oganov RG, Suvorova EI, Khudyakov MB, Baranova EI, Konradi AO, Shlyakhto EV, Ilyin VA, Kasimov RA, Shabunova AA, Kalashnikov KN, Kalachikova ON, Kondakova OA, Popov AV, Ustinova NA Azarin OG, Babenko NI, Bondartsov LV, Minakov EV, Khvostikova AE, Furmenko GI, Nedogoda SV, Ledyayeva AA, Chumachek EV, Kulakova NV, Mokshina MV, Nevzorova VA, Rodionova LV, Shestakova NV, Belova OA, Nazarova OA, Romanchuk SV, Shutemova EA, Kaveshnikov SV, Karpov RS et al. Awareness and features of statin therapy in persons with different cardiovascular risk: ESSAY-RF study. Cardiovascular Therapy and Prevention 2016;15(4):29-37 (In Russian).
39. Boytsov SA, Yakushin SS, Martsevich SYu, Lukyanov MM, Nikulina NN, Zagrebelniy AV, Vorobyev AN, Pereverzeva KG, Pravkina EA, Deyev AD, Andreyenko EYu, Yershova AI, Meshkov AN, Myasnikov RP, Serdyuk SE, Kharlap MS. Outpatient register of cardiovascular diseases in the Ryazan region (REQUAZA): objectives, experience and first results. Rational Pharmacotherapy in Cardiology 2013;9(1):4-14 (In Russian).
40. De Backer G, Jankowskib P, Kotseva K, Mirrakhimov E, Reinere Ž, Rydénf L, Tokgözoğlug L, Wood D, De Bacquer D; EUROASPIRE V collaborators; Writing Committee; Scientific Steering/ Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019 Jun;285:135-46.
41. Akhmedzhanov NM, Nebiyeridze DV, Safaryan AS, Vygodin VA, Shurayev AYu, Tkacheva ON, Lishuta AS. Analysis of hypercholesterolemia prevalence in outpatient practice (according to ARGO study): part I. Rational Pharmacotherapy in Cardiology 2015;11(3):253-60 (In Russian).
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]